30 results on atopic dermatitis
Primary objectives • To characterize the histamine dose response on pruritus• To profile the response to intradermal histamine by:o Clinical measureso Biophysical measureso Imagingo Molecular and cellular responsesSecondary objective • Comparison to…
The purpose of this study is to assess short-term and the long-term safety and efficacy of oral ZPL389 (30 mg once daily (o.d.) and 50 mg o.d.) when used concomitantly or intermittently with topical corticosteroid (TCS) and/or topical calcineurin…
The objective of this study is to evaluate the efficacy and safety of upadacitinib versus dupilumab for the treatment of adult subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.
BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) NL is part of the BIOMAP consortium, which is a EU-funded consortium through which various research projects will address three main unmet needs in AD and Pso with a broad impact on disease…
What has so far been underexplored in the study of molecular signatures in atopic dermatitis is a wide systems biology approach, in which multiple analysis techniques (a so-called multi-omics approach) are applied in a clinical setting where…
To explore associations between biomarkers of atopic dermatitis(AD) and:• Disease state and time course of AD,• Disease state and evolution of selected atopiccomorbid conditions,• Effectiveness of specific AD treatments.
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
The purpose of this study is to investigate how safe the new compound RPT193 is when it is administered to healthy subjects. RPT193 has not been administered to humans before. It has been previously tested in the laboratory and on animals. RPT193…
The effectiveness and cost-effectiveness of treatment with systemic cyclosporine or dupilumab in children with moderate-to-severe atopic dermatitis is different for patients with low NMF (corresponding with filaggrine-gene mutation) versus children…
The primary objective of the study is to evaluate the efficacy of REGN3500monotherapy compared with placebo treatment in adult patients withmoderate-to-severe atopic dermatitis (AD).The secondary objectives of the study are:* To evaluate the…
The current study has two main objectives:- To investigate if the effectiveness of CsA differs for NMF low vs. NMF normal (corresponding with FLG mutation vs. FLG wild type) in children with moderate-to-severe AD. - To investigate if the…
Primary ObjectiveTo assess the efficacy of Gladskin Eczema Cream BID in patients with mild to moderate AD as assessed by EASI ScoreSecondary Objectives* To assess the pharmacodynamic effects of Gladskin Eczema Cream on the skin-microbiome, with…
Gladskin cream will decrease the presence of Staphylococcus aureus and thereby will improve the clinical picture of the eczema patients.
The goal of this study is to assess the effectiveness of antibacterial clothing based on silver or chitosan on the doctor-reported AD severity in patients with moderate to severe AD. Secondary goals are to retrieve information about the effect of…
Antimicrobial therapeutic clothing are more effective in reducing the severity of atopic dermatitis than non-antimicrobial therapeutic clothing
To assess the safety and efficacy of DBV712 in initiating desensitisation of peanut in children aged 1 to 3 years with peanut allergy, after 12 months of treatment with Epicutaneous Immunotherapy EPIT).
To assess the long-term safety and tolerability of LOU064 in patients with CSU who have participated in preceding studies with LOU064.
Our objectives in both adult and paediatric psoriasis patients are (I) To validate the Handheld LSCI Device for visualization of vascular changes within psoriatic plaques. (II) Identification of the most active and least active sides of psoriatic…
Primary* To evaluate the effect of EDP1066 in multiple formulations on the systemic immune system.Secondary* To evaluate the safety and tolerability of EDP1066 in multiple formulations.
Primary objectiveTo assess the efficacy of tildrakizumab treatment (as assessed by PASI 75) in moderate-to-severe plaque psoriasis patients who are non-responders to DMF. Secondary objectivesTildrakizumab- To assess the efficacy of tildrakizumab…